The effectiveness of vaccination against XXXX in healthy, working adults.

@entity1 @entity683 @entity1576
BACKGROUND: Although @entity683 causes substantial morbidity and mortality in all age groups, current recommendations emphasize annual immunization for @entity1 at high risk for complications of @entity683 . We conducted a double-blind, placebo-controlled trial of vaccination against @entity683 in healthy, working adults. METHODS: In the fall of 1994, we recruited working adults from 18 to 64 years of age from in and around the Minneapolis-St. Paul area and randomly assigned them to receive either @entity683 vaccine or placebo injections. The primary study outcomes included upper @entity1576 , absenteeism from work because of upper @entity1576 , and visits to physicians' offices for upper @entity1576 . The economic benefits of vaccination were analyzed by estimating the direct and indirect costs associated with immunization and with upper @entity1576 . RESULTS: We enrolled a total of 849 subjects. Baseline characteristics were similar in the two groups. During the follow-up period, consisting of the 1994-1995 @entity683 season (December 1, 1994, through March 31, 1995), those who received the vaccine reported 25 percent fewer episodes of upper @entity1576 than those who received the placebo (105 vs. 140 episodes per 100 subjects, P < 0.001), 43 percent fewer days of sick leave from work due to upper @entity1576 (70 vs. 122 days per 100 subjects, P = 0.001), and 44 percent fewer visits to physicians' offices for upper @entity1576 (31 vs. 55 visits per 100 subjects, P = 0.004). The cost savings were estimated to be  46.85 per @entity1 vaccinated. CONCLUSIONS: Vaccination against @entity683 has substantial health-related and economic benefits for healthy, working adults.
